Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $10.3 million.

  • Allogene Therapeutics' Other Non-Current Assets changed negligibly% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $10.3 million for FY2024, which is negligibly% changed negligibly from last year.
  • Allogene Therapeutics' Other Non-Current Assets amounted to $10.3 million in FY2024, which was down 0.00% from $10.3 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Other Non-Current Assets registered a high of $10.3 million during FY2021, and its lowest value of $9.4 million during FY2020.
  • In the last 3 years, Allogene Therapeutics' Other Non-Current Assets had a median value of $10.3 million in 2024 and averaged $10.3 million.
  • Data for Allogene Therapeutics' Other Non-Current Assets shows a peak YoY spiked of 104.61% (in 2020) over the last 5 years.
  • Over the past 5 years, Allogene Therapeutics' Other Non-Current Assets (Yearly) stood at $9.4 million in 2020, then climbed by 8.92% to $10.3 million in 2021, then remained steady at $10.3 million in 2022, then remained steady at $10.3 million in 2023, then remained steady at $10.3 million in 2024.